Physician profile
William P Abide
NPI 1932307261
$4,173.41
in general payments reported to CMS, 2019-2025
33 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $358 · 2021: $852 · 2022: $773 · 2023: $620 · 2024: $640 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $674.53 | 2019-2025 | Cardiomems, Jot Dx |
| Novartis Pharmaceuticals Corporation | $448.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $445.96 | 2019-2024 | Xarelto |
| Pfizer INC. | $440.08 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $360.99 | 2020-2025 | Lifevest |
| Amgen INC. | $302.10 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $218.86 | 2022-2023 | Evkeeza, Praluent |
| Boston Scientific Corporation | $174.08 | 2019-2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $164.25 | 2019-2024 | |
| Amarin Pharma, INC. | $109.13 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.85 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $78.90 | 2021-2023 | Verquvo |
| Endotronix, INC. | $70.55 | 2021-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Bayer Healthcare Pharmaceuticals INC. | $67.28 | 2021 | |
| Abiomed | $60.19 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $56.91 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Astrazeneca Pharmaceuticals LP | $47.99 | 2019-2023 | Brilinta |
| Alnylam Pharmaceuticals INC. | $41.65 | 2022 | |
| Strongbridge US INC. | $40.56 | 2020 | |
| Heartflow, INC. | $25.74 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $24.99 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $24.59 | 2022 | |
| Genzyme Corporation | $23.98 | 2025 | |
| Vital Connect, INC | $23.89 | 2023 | Vitalpatch Rtm |
| Cvrx, INC. | $22.44 | 2021-2022 | |
| Acist Medical Systems, INC. | $21.45 | 2025 | |
| Chiesi USA, INC. | $18.87 | 2023 | Kengreal |
| Scpharmaceuticals INC. | $17.11 | 2024 | |
| Agepha Pharma Fz LLC | $16.49 | 2024 | Lodoco |
| Tactile Systems Technology INC | $15.05 | 2020 | |
| Teleflex LLC | $14.82 | 2021 | |
| Esperion Therapeutics, INC. | $13.12 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Abide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.